Roivant's ulcerative colitis drug from Pfizer shows promising data in early readout Roivants ulcerative colitis drug acquired from Pfizer last month has already produced positive data in the first readout of the Phase IIb trial
10.2337/db10-0195 10.2337/db10-0195 [DOI] [PMC free article] [PubMed] [Google Scholar] Chew EY, Clemons TE, Agrn E et al (2015) Age-Related Eye Disease Study 2 (AREDS2) Research Group
The timeline for results can vary from person to person, as everyone's body chemistry is unique
Medical weight loss injections work by mimicking natural hormones that regulate appetite and blood sugar
doi: 10.1038/nature16549 133 YilmazMYalcinEPresumeyJAwEMaMWhelanCWet al
Despite its efficacy, EAs therapeutic use is limited by its diuretic side effects and lack of specificity, prompting the development of derivatives and analogs to improve its selectivity and potency (Tew and Gat, 2001